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Summary
Background Brain scans are essential to exclude haemorrhage in patients with suspected acute ischaemic stroke 
before treatment with alteplase. However, patients with early ischaemic signs could be at increased risk of haemorrhage 
after alteplase treatment, and little information is available about whether pre-existing structural signs, which are 
common in older patients, aﬀ ect response to alteplase. We aimed to investigate the association between imaging 
signs on brain CT and outcomes after alteplase.
Methods IST-3 was a multicentre, randomised controlled trial of intravenous alteplase (0·9 mg/kg) versus control 
within 6 h of acute ischaemic stroke. The primary outcome was independence at 6 months (deﬁ ned as an Oxford 
Handicap Scale [OHS] score of 0–2). 3035 patients were enrolled to IST-3 and underwent prerandomisation brain CT. 
Experts who were unaware of the random allocation assessed scans for early signs of ischaemia (tissue hypoattenuation, 
infarct extent, swelling, and hyperattenuated artery) and pre-existing signs (old infarct, leukoaraiosis, and atrophy). In 
this prespeciﬁ ed analysis, we assessed interactions between these imaging signs, symptomatic intracranial 
haemorrhage (a secondary outcome in IST-3) and independence at 6 months, and alteplase, adjusting for age, National 
Institutes of Health Stroke Scale (NIHSS) score, and time to randomisation. This trial is registered at ISRCTN.com, 
number ISRCTN25765518.
Findings 3017 patients were assessed in this analysis, of whom 1507 were allocated alteplase and 1510 were 
assigned control. A reduction in independence was predicted by tissue hypoattenuation (odds ratio 0∙66, 95% CI 
0∙55–0∙81), large lesion (0∙51, 0∙38–0∙68), swelling (0∙59, 0∙46–0∙75), hyperattenuated artery (0∙59, 0∙47–0∙75), 
atrophy (0∙74, 0∙59–0∙94), and leukoaraiosis (0∙72, 0∙59–0∙87). Symptomatic intracranial haemorrhage was 
predicted by old infarct (odds ratio 1∙72, 95% CI 1∙18–2∙51), tissue hypoattenuation (1∙54, 1∙04–2∙27), and 
hyperattenuated artery (1∙54, 1∙03–2∙29). Some combinations of signs increased the absolute risk of symptomatic 
intracranial haemor rhage (eg, both old infarct and hyperattenuated artery, excess with alteplase 13∙8%, 95% CI 
6∙9–20∙7; both signs absent, excess 3∙2%, 1∙4–5∙1). However, no imaging ﬁ ndings—individually or combined—
modiﬁ ed the eﬀ ect of alteplase on independence or sympto matic intracranial haemorrhage.
Interpretation Some early ischaemic and pre-existing signs were associated with reduced independence at 6 months 
and increased symptomatic intracranial haemorrhage. Although no interaction was noted between brain imaging 
signs and eﬀ ects of alteplase on these outcomes, some combinations of signs increased some absolute risks. Pre-
existing signs should be considered, in addition to early ischaemic signs, during the assessment of patients with 
acute ischaemic stroke.
Funding UK Medical Research Council, Health Foundation UK, Stroke Association UK, Chest Heart Stroke Scotland, 
Scottish Funding Council SINAPSE Collaboration, and multiple governmental and philanthropic national funders. 
Copyright © The IST-3 collaborative group. Open access article distributed under the terms of CC BY.
Lancet Neurol 2015; 14: 485–96 
Published Online
March 27, 2015
http://dx.doi.org/10.1016/
S1474-4422(15)00012-5
See Comment page 458
*Collaborators are listed in the 
appendix pp 2–5
Correspondence to:
Prof J M Wardlaw, Brain 
Research Imaging Centre, Centre 
for Clinical Brain Sciences, 
University of Edinburgh, 
Western General Hospital, 
Edinburgh EH4 2XU, UK
joanna.wardlaw@ed.ac.uk
See Online for appendix
Introduction
Prompt treatment with intravenous alteplase improves 
independent survival after acute ischaemic stroke.1,2 
However, concerns about the risk of symptomatic intra-
cranial haemorrhage and whether patients with early 
signs of ischaemia on CT should receive alteplase could 
be deterring use of this treatment.3
Early signs of ischaemia on non-enhanced brain CT 
include tissue hypoattenuation, lesion swelling, and 
arterial hyperattenuation from occlusive thrombus. 
Tissue hypoattenuation might represent irreversible 
tissue damage4 and has been associated with increased 
risk of symptomatic intracranial haemorrhage in some,5 
but not all,6,7 studies. These signs are rarely seen alone, 
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but the association between combinations of signs and 
prognosis after stroke or their interaction with alteplase 
is unknown. Moreover, in some alteplase trials, patients 
with speciﬁ c ﬁ ndings (eg, extensive tissue hypo-
attenuation) were excluded.5,8
Other pathological features—such as leukoaraiosis, 
cerebral atrophy, and old infarcts—are often seen on 
brain CT in patients with acute stroke. These pre-existing 
signs might indicate brain frailty9,10 (ie, a vulnerability to 
ischaemia) or increased risk of symptomatic intracranial 
haemorrhage.11 The association of pre-existing signs with 
response to alteplase, with or without early ischaemic 
signs, is unknown.
The third International Stroke Trial (IST-3)12 is the 
largest (n=3035) randomised controlled trial of alteplase 
in acute stroke to date1,2 and was designed to test 
whether a wider range of patients could beneﬁ t from 
alteplase up to 6 h after stroke. The primary endpoint of 
IST-3—an increase in independent survival (deﬁ ned as 
an Oxford Handicap Scale [OHS] score of 0–2 at 
6 months)—did not diﬀ er between alteplase and control 
groups (odds ratio 1·13, 95% CI 0·95–1·35; p=0·181);12 
however, in prespeciﬁ ed secondary analyses (ordinal 
shift analysis of the OHS and an OHS score of 0–1), 
alteplase increased functional outcome in all patients 
randomised up to 6 h and increased the primary 
outcome in the patients treated less than 3 h after 
stroke. The eﬀ ect of alteplase 18 months after stroke 
has been published elsewhere.13 The ﬁ ndings of IST-3 
accord with those of previous alteplase trials, at all time 
windows.2
A secondary objective of IST-3 was to ascertain 
whether early ischaemic or pre-existing brain CT 
signs—indivi dually or in combination—were associated 
with response to alteplase on several clinically relevant 
early and late outcomes.14 Here, we present that 
secondary analysis.
Methods
Study design and participants
IST-3 was an international, multicentre, open-label, 
prospective blinded endpoint, randomised controlled 
trial done at 156 centres in 12 countries (appendix 
pp 2–5). Patients were eligible for the study if the treating 
clinician felt there was no clear indication for or 
contraindication to alteplase and judged the treatment 
promising but unproven for that individual. Eligibility 
criteria were age 18 years or older (no upper age limit) 
and symptoms of cortical, lacunar, and posterior 
circulation stroke,15 of all severities, according to the 
National Institutes of Health Stroke Scale (NIHSS). 
All participants had to be able to undergo randomisation 
and start treatment within 6 h of stroke. We did not 
exclude patients with early ischaemic or pre-existing 
imaging signs on brain CT. We excluded individuals 
younger than 18 years, people with standard con tra-
indications to alteplase, patients with established visible 
infarction (ie, indicating stroke onset was likely to be 
more than 6 h previously), and individuals with 
haemorrhagic stroke or non-stroke lesion as the cause of 
stroke.
The IST-3 protocol16 and statistical analysis plan14 have 
been published elsewhere. The study was approved by the 
Scotland A research ethics committee and by ethics 
committees and other regulatory bodies of all partici-
pating countries, hospitals, and institutions. All patients, 
or a relative if the patient lacked capacity, provided written 
informed consent before randomisation into the trial.
Randomisation and masking
Full details of the IST-3 randomisation procedure, 
including the minimisation process, are presented 
elsewhere.12,16 Brieﬂ y, the randomising clinician recorded 
baseline data via a central, secure, telephone-based or 
web-based system. The system randomly allocated 
patients to either standard best medical care plus 
immediate thrombo lysis with intravenous alteplase 
(0·9 mg/kg bodyweight; maximum 90 mg; 10% bolus 
with the remainder over 1 h) or control (standard best 
medical care alone) within 6 h of ischaemic stroke. 
Patients allocated to the control group received the same 
stroke care as did individuals allocated to the alteplase 
group. The ﬁ rst 276 patients enrolled to the study were 
treated in a placebo-controlled, double-blind phase (the 
placebo was an inert product identical in appearance to 
alteplase); thereafter, patients were randomised to either 
immediate alteplase or open control.
Procedures
To be approved for inclusion in IST-3, all participating 
centres had to pass minimum image acquisition 
standards16 to ensure that brain scans were of diagnostic 
quality for acute stroke (for CT) and included the 
minimum correct sequences (for MRI). Before 
randomisation, all patients had either a CT or MRI 
3035 patients enrolled, scanned and assessed 
by a local clinician or radiologist 
3035 patients randomly assigned 
8 scans not received at  
central trials oﬃce 
  
10 scans not received at  
central trials oﬃce 
  
1515 assigned alteplase and assessed
at 7 days and 6 months
1520 assigned control and assessed
at 7 days and 6 months
1507 scans adjudicated at central
trials oﬃce and clinical and
imaging data included in 
primary analysis
1510 scans adjudicated at central
trials oﬃce and clinical and
imaging data included in 
primary analysis
Figure 1: Trial proﬁ le
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brain scan, repeated 24–48 h after stroke and again if 
any neurological deterioration arose in the ﬁ rst 7 days. 
The present analysis concerns brain images taken 
before randomisation, up to 6 h after stroke.
Participating centres sent all brain images to the IST-3 
coordinating centre for adjudication and quality 
checking; all scans were anonymised. Adjudicators were 
masked to all information, except whether the scan was 
prerandomisation or follow-up. They viewed the images 
and recorded their ratings on a secure web-based system 
(systematic image review system [SIRS]). All adjudicators 
were neuroradiologists (JMW, RvK, AvH, LC, NB, ZM, 
AF, GP) or stroke neurologists (AP, AA) with experience 
in stroke imaging; they rated 60 scans from the ACCESS 
study17,18 and 25 scans from IST-3 that were selected at 
random, to ensure satisfactory agreement (deﬁ ned as 
κ>0·70) for presence of early ischaemic signs and no 
more than one category diﬀ erence for pre-existing signs. 
Adjudicators completed all analyses before the database 
was locked and the randomisation code was broken. 
Every scan was read by one adjudicator. Any discrepancies 
For more on SIRS see http://
www.neuroimage.co.uk
Alteplase 
(n=1507)
Control 
(n=1510)
(Continued from previous column)
Early ischaemic lesion size†
None visible 885 (59%) 914 (61%)
Small 110 (7%) 97 (6%)
Medium 250 (17%) 250 (17%)
Large 124 (8%) 137 (9%)
Very large 138 (9%) 112 (7%)
ASPECTS score‡
0–4 162 (11%) 138 (9%)
5–7 201 (13%) 228 (15%)
8–10 1144 (76%) 1144 (76%)
Early ischaemic lesion depth of tissue hypoattenuation§
None 892 (59%) 922 (61%)
Mild 503 (33%) 492 (33%)
Severe 112 (7%) 96 (6%)
Early ischaemic lesion degree of swelling
None 1152 (76%) 1171 (78%)
Mild sulcal eﬀ acement 283 (19%) 265 (18%)
Mild ventricular eﬀ acement 71 (5%) 73 (5%)
Moderate eﬀ acement 1 (<1%) 0
Severe eﬀ acement 0 1 (<1%)
Location of hyperattenuated arteries
None 1131 (75%) 1151 (76%)
Anterior circulation 360 (24%) 342 (23%)
Posterior circulation 16 (1%) 17 (1%)
ICA, or BA, or MCA and ACA 42 (3%) 33 (2%)
MCA, or ACA, or PCA main 334 (22%) 326 (22%)
Pre-existing brain changes
Evidence of atrophy 1161 (77%) 1166 (77%)
Evidence of leukoaraiosis 765 (51%) 782 (52%)
Evidence of old infarcts 685 (45%) 651 (43%)
Evidence of non-stroke lesions 73 (5%) 77 (5%)
Data are number of patients (%). ACA=anterior cerebral artery. ASPECTS=Alberta 
Stroke Program Early CT Stroke. BA=basilar artery. ICA=internal carotid artery. 
IST-3=third International Stroke Trial. MCA=middle cerebral artery. 
NIHSS=National Institutes of Health Stroke Scale. PCA=posterior cerebral artery. 
*Assesses neurological deﬁ cit in stroke. †Refers to IST-3 image reading 
categorisation of lesion extent (all vascular territories). ‡Assesses the extent of 
infarct aﬀ ecting the MCA territory by subtracting a point for each of ten regions 
that are involved in the acute ischaemic lesion. §Classed as mild (ie, grey matter 
attenuation had become the same as normal white matter) or severe (ie, grey 
and white matter attenuation less than normal white matter).
Table 1: Baseline clinical and imaging variables 
Alteplase 
(n=1507)
Control 
(n=1510)
Age (years)
≤80 693 (46%) 715 (47%)
>80 814 (54%) 795 (53%)
18–50 58 (4%) 68 (5%)
51–60 98 (7%) 102 (7%)
61–70 187 (12%) 175 (12%)
71–80 350 (23%) 370 (25%)
81–90 703 (47%) 697 (46%)
>90 111 (7%) 98 (6%)
NIHSS score*
0–5 303 (20%) 304 (20%)
6–10 419 (28%) 428 (28%)
11–15 304 (20%) 295 (20%)
16–20 268 (18%) 271 (18%)
>20 213 (14%) 212 (14%)
Time to randomisation (h)
0 to ≤3 431 (29%) 415 (27%)
>3 to ≤4·5 575 (38%) 596 (39%)
>4·5 to ≤6 501 (33%) 497 (33%)
>6 0 2 (<1%)
Randomising clinician’s assessment of acute ischaemic change on 
prerandomisation imaging
No change 890 (59%) 892 (59%)
Possibly change 359 (24%) 339 (22%)
Deﬁ nitely change 258 (17%) 279 (18%)
Expert reader’s assessment of acute ischaemic change on 
prerandomisation imaging
Scan completely normal 140 (9%) 129 (9%)
Scan not normal but no sign of any early 
ischaemic change
743 (49%) 781 (52%)
Signs of any early ischaemic change 624 (41%) 600 (40%)
Early ischaemic lesion territory
Indeterminate 885 (59%) 914 (61%)
MCA or ACA or border zone 589 (39%) 555 (37%)
Posterior 22 (1%) 36 (2%)
Lacunar 11 (1%) 5 (<1%)
Early ischaemic lesion changes in MCA territory
None 925 (61%) 960 (64%)
One-third or less 357 (24%) 354 (23%)
More than one-third 225 (15%) 196 (13%)
(Table 1 continues in next column)
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between the scan rating and clinical data (eg, side of 
brain aﬀ ected, presence of haemorrhage) identiﬁ ed 
during data cleaning before data lock were cross-checked 
by JMW, who assigned a ﬁ nal rating before unmasking 
took place and the randomisation code was broken.
We ﬁ rst checked brain CTs for early ischaemic signs 
(tissue hypoattenuation, lesion size, swelling, and 
hyperattenuated artery); we used the term visible infarct 
to represent any of these signs. We then looked for 
pre-existing structural signs (old infarcts, leukoaraiosis, 
and atrophy).19 We classiﬁ ed images using validated 
scores.17,18 We classed scans as normal only if no early 
ischaemic changes or pre-existing changes were present.
We deﬁ ned the presence and degree of hypoattenuated 
tissue as either mild (grey matter attenuation equal to 
normal white matter) or severe (grey and white matter 
attenuation slightly less than normal white matter but 
still consistent with onset of stroke within 6 h).20 
We classiﬁ ed the extent of acute ischaemic lesions in 
three ways: with the one-third middle cerebral artery 
(MCA) method;21,22 with the IST-3 method;17,23 and with 
the Alberta Stroke Program Early CT Stroke (ASPECTS) 
score.24 The IST-3 score for infarct extent reﬂ ects all 
arterial territories, whereas the ASPECTS score and one-
third MCA method focus only on the MCA territory. 
Therefore, we used the IST-3 score as the primary 
measure of infarct size in analyses, condensing the full 
IST-3 lesion extent score into four groups for analysis: 
small infarcts, which we deﬁ ned as lacunar, small 
cortical, small cerebellar, less than half of brainstem, or 
less than half of the anterior cerebral artery (ACA) or 
posterior cerebral artery (PCA) territory; medium 
infarcts, classed as striatocapsular, the anterior or 
posterior half of the peripheral MCA territory, or more 
than half the ACA or PCA territory; large infarcts, 
deﬁ ned as the whole of the peripheral MCA territory or 
all the MCA territory; and very large infarcts, which 
comprised the whole MCA and PCA territory, all the 
MCA and ACA territory, or all three territories.24 Small 
infarcts on the IST-3 score were equivalent to ASPECTS 
8–10, medium infarcts corresponded to ASPECTS 5–7, 
and large and very large infarcts were similar to 
ASPECTS 0–4. MCA involvement in small and medium 
infarcts (according to IST-3 score) was equivalent to less 
than one-third MCA, and in large and very large infarcts 
it corresponded to more than one-third MCA. We graded 
ischaemic lesion swelling on a seven-point scale.23 We 
noted the presence or absence and location of any 
hyperattenuated artery.17,25
We recorded the location of old infarcts (eg, cortical, 
lacunar, border zone, and brainstem or cerebellar).23 
We noted the presence and severity of leukoaraiosis on 
CT;26 if brain MRI was done, we used the Fazekas scale to 
grade changes.27 We classiﬁ ed atrophy as none, moderate, 
or severe when compared against standard examples. 
We also classed follow-up scans for any haemorrhage 
(petechial, haematoma in or remote from infarct, 
intra ventricular, or subarachnoid blood), including 
whether the haemorrhage was likely to worsen neuro -
logical status, as part of the outcome assessment for 
symptomatic intracranial haemorrhage.
Outcomes
The primary outcome of IST-3 was the proportion of 
patients alive and independent, deﬁ ned by an OHS score 
of 0–2, at 6 months. The OHS28 is similar to the modiﬁ ed 
Rankin scale29,30 and has values from 0 to 6, with 
0 representing no symptoms or completely independent 
and 6 signifying the patient has died. OHS score 0–2 
indicates good functional outcome. We also analysed 
two prespeciﬁ ed secondary endpoints:14 an ordinal analysis 
of the OHS; and OHS score of 0–1 (ie, favourable 
Age, adjusted for NIHSS score NIHSS score, adjusted for age Delay, adjusted for age and NIHSS score
Odds ratio (95% CI) p Odds ratio (95% CI) p Odds ratio (95% CI) p
Early ischaemic signs
Visible infarct 0·98 (0·97–0·98) <0·0001 1·11 (1·09–1·12) <0·0001 1·08 (1·01–1·16) 0·019
Hypoattenuation 0·98 (0·97–0·98) <0·0001 1·10 (1·09–1·12) <0·0001 1·10 (1·03–1·18) 0·006
Large lesion* 0·98 (0·97–0·99) <0·0001 1·11 (1·09–1·13) <0·0001 1·03 (0·94–1·12) 0·561
Swelling 0·98 (0·97–0·99) <0·0001 1·09 (1·08–1·11) <0·0001 1·04 (0·96–1·13) 0·302
Hyperattenuated artery 0·98 (0·97–0·98) <0·0001 1·10 (1·09–1·12) <0·0001 1·02 (0·94–1·10) 0·664
Pre-existing signs
Atrophy 1·11 (1·10–1·12) <0·0001 0·99 (0·98–1·00) 0·179 0·98 (0·89–1·07) 0·621
Leukoaraiosis 1·09 (1·08–1·09) <0·0001 0·99 (0·98–1·00) 0·221 0·99 (0·93–1·06) 0·843
Old infarct 1·03 (1·03–1·04) <0·0001 0·99 (0·98–1·00) 0·017 0·98 (0·92–1·05) 0·566
Associations for visible infarct (the summary variable) are provided for completeness. Odds ratios and 95% CIs indicate the increased or decreased odds of the imaging sign 
being present for a 1 point change in NIHSS score, a 1 year change in age, or a 1 h increase in time to randomisation. Each of the eight imaging variables was used separately 
in two logistic regressions: ﬁ rst on age and NIHSS score (both linear) to give the values in the ﬁ rst two pairs of columns; and second on age, NIHSS score, and time to 
randomisation (all linear) to give the values in the last pair of columns. IST-3=third International Stroke Trial. NIHSS=National Institutes of Health Stroke Scale. *Large lesion 
deﬁ ned as a combination of large and very large on IST-3 score.
Table 2: Logistic linear regression analysis of associations between imaging signs and age, NIHSS score, and time to randomisation
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outcome). Other secondary outcomes were symptomatic 
intracranial haemor rhage within 7 days,14 death within 
7 days, and death by 6 months. 
Local staﬀ  at every centre followed up all patients for 
7 days and recorded early outcomes (symptomatic 
intracranial haemorrhage, death, and likely cause of 
death before 7 days), which were sent to the central trials 
oﬃ  ce. At 6-month follow-up, central researchers who 
were masked to group allocations sent questionnaires by 
post to patients or their carers, to record independence 
(using the OHS);16 if we knew the patient had died, 
we sent the questionnaire to their family doctor, to obtain 
the date of death and likely cause.
Statistical analyses
Analyses of early ischaemic and pre-existing structural 
brain signs, their eﬀ ect on functional outcome, death, 
and symptomatic intracranial haemorrhage, and 
interactions with alteplase, were prespeciﬁ ed in the trial 
protocol and analysis plan.14 We analysed imaging data 
for patients whose prerandomisation scans were received 
at the central trials oﬃ  ce. We did statistical analyses with 
SAS version 9.3.
We used logistic regression to ascertain associations 
between imaging signs and: (a) age, NIHSS score, and 
time to randomisation; and (b) outcomes at 7 days 
(symptomatic intracranial haemorrhage) and 6 months 
(OHS score of 0–2 and OHS score of 0–1), which were 
judged representative of the most clinically relevant 
early hazard and late beneﬁ t. We did multivariate 
logistic regression, adjusting for the linear eﬀ ects of 
OHS score 0–2 versus 
OHS score 3–6
Symptomatic intracranial 
haemorrhage
Odds ratio (95% CI) p Odds ratio (95% CI) p
Age (years) 0·96 (0·96–0·97) <0·0001 1·00 (0·98–1·02) 0·911
NIHSS score 0·83 (0·82–0·85) <0·0001 1·06 (1·03–1·10) <0·0001
Time to randomisation (h) 1·04 (0·96–1·13) 0·303 0·98 (0·83–1·16) 0·814
Alteplase versus control 1·13 (0·94–1·35) 0·192 6·65 (3·89–11·35) <0·0001
Antiplatelets at the time of stroke 
versus none
·· <0·0001 1·60 (1·07–2·38) 0·021
Large or very large lesion versus 
small, medium, or no lesion
0·69 (0·49–0·99) 0·043 0·97 (0·55–1·72) 0·919
Swelling 0·79 (0·56–1·11) 0·168 0·95 (0·54–1·69) 0·867
Hyperattenuated artery 0·70 (0·54–0·91) 0·007 1·45 (0·92–2·28) 0·114
Mild tissue hypoattenuation versus 
none
1·11 (0·52–2·38) 0·783 0·68 (0·17–2·78) 0·588
Severe tissue hypoattenuation versus 
none
1·40 (0·61–3·21) 0·432 0·71 (0·15–3·26) 0·658
Old infarcts 0·90 (0·74–1·09) 0·278 1·75 (1·17–2·63) 0·007
Mild leukoaraiosis versus none 0·81 (0·65–1·00) 0·051 1·01 (0·64–1·59) 0·975
Severe leukoaraiosis versus none 0·64 (0·48–0·85) 0·002 0·92 (0·51–1·66) 0·772
Mild atrophy versus none 0·87 (0·67–1·12) 0·273 0·83 (0·47–1·48) 0·532
Severe atrophy versus none 0·72 (0·52–1·00) 0·052 0·82 (0·40–1·67) 0·590
Numbers of patients in each category are shown in table 1. Odds ratios indicate the increased or decreased odds of the 
outcome being present for a 1 year increase in age, a 1 point increase in NIHSS score, or a 1 h increase in time to 
randomisation. Hosmer-Lemeshow tests for lack of ﬁ t: OHS outcome, p=0·59; symptomatic intracranial haemorrhage 
outcome, p=0·76. Additional time windows are shown in the appendix (pp 8–9). NIHSS=National Institutes of Health 
Stroke Scale. OHS=Oxford Handicap Scale.
Table 4: Full multivariate logistic regression models for symptomatic intracranial haemorrhage and 
functional outcome at 6 months
Symptomatic intracranial 
haemorrhage
Death at 7 days or before Death at 6 months or before Alive and independent 
(OHS score 0–2)
Favourable outcome 
(OHS score 0–1)
Odds ratio 
(95% CI)
p Odds ratio 
(95% CI)
p Odds ratio 
(95% CI)
p Odds ratio 
(95% CI)
p Odds ratio 
(95% CI)
p
Early ischaemic signs
Visible infarct 1·48 (1·00–2·19) 0·049 1·64 (1·24–2·16) 0·0004 1·39 (1·15–1·68) 0·0007 0·67 (0·55–0·81) <0·0001 0·63 (0·51–0·79) <0·0001
Hypoattenuation* 1·54 (1·04–2·27) 0·032 1·64 (1·25–2·16) 0·0004 1·39 (1·15–1·68) 0·0007 0·66 (0·55–0·81) <0·0001 0·62 (0·50–0·78) <0·0001
Severe hypoattenuation† 1·31 (0·67–2·56) 0·432 1·04 (0·63–1·74) 0·872 0·92 (0·63–1·33) 0·649 0·87 (0·60–1·27) 0·482 0·78 (0·51–1·19) 0·246
Large or very large lesion‡ 1·32 (0·85–2·05) 0·218 2·22 (1·67–2·96) <0·0001 2·07 (1·64–2·60) <0·0001 0·51 (0·38–0·68) <0·0001 0·40 (0·28–0·58) <0·0001
Very large lesion§ 1·51 (0·89–2·57) 0·131 3·20 (2·29–4·47) <0·0001 2·28 (1·68–3·11) <0·0001 0·29 (0·17–0·47) <0·0001 0·22 (0·10–0·46) <0·0001
Swelling 1·31 (0·87–1·97) 0·199 1·55 (1·17–2·06) 0·002 1·43 (1·16–1·77) 0·0008 0·59 (0·46–0·75) <0·0001 0·55 (0·41–0·73) <0·0001
Hyperattenuated arteries 1·54 (1·03–2·29) 0·034 1·44 (1·09–1·91) 0·009 1·41 (1·15–1·73) 0·001 0·59 (0·47–0·75) <0·0001 0·63 (0·48–0·83) 0·001
Pre-existing signs
Any leukoaraiosis¶ 1·01 (0·68–1·50) 0·967 1·09 (0·82–1·45) 0·536 1·38 (1·14–1·67) 0·001 0·72 (0·59–0·87) 0·0007 0·62 (0·50–0·76) <0·0001
Severe leukoaraiosis|| 1·15 (0·77–1·70) 0·499 1·17 (0·89– 1·54) 0·267 1·43 (1·18–1·72) 0·0002 0·66 (0·54–0·80) <0·0001 0·62 (0·50–0·78) <0·0001
Atrophy** 0·97 (0·58–1·64) 0·917 0·83 (0·57–1·20) 0·315 1·22 (0·93–1·60) 0·149 0·74 (0·59–0·94) 0·013 0·64 (0·50–0·82) 0·0004
Severe atrophy†† 1·02 (0·64–1·63) 0·923 0·87 (0·63–1·22) 0·422 1·28 (1·03–1·59) 0·026 0·79 (0·63–1·01) 0·057 0·75 (0·57–0·99) 0·040
Old infarct 1·72 (1·18–2·51) 0·005 0·94 (0·72–1·22) 0·622 1·05 (0·87–1·26) 0·603 0·88 (0·73–1·05) 0·149 0·79 (0·64–0·96) 0·017
Associations for visible infarct (the summary variable) are provided for completeness. The odds ratio is the estimated odds of an outcome happening when the imaging feature is present, divided by the odds of 
an outcome happening when the imaging feature is absent. NIHSS=National Institutes of Health Stroke Scale. OHS=Oxford Handicap Scale. *Mild or severe hypoattenuation versus none. †Severe 
hypoattenuation versus mild or none. ‡Large or very large lesion versus no lesion or small or medium lesion. §Very large lesion versus no lesion or small, medium, or large lesion. ¶Mild or severe leukoaraiosis 
versus none. ||Severe leukoaraiosis versus mild or none. **Moderate or severe atrophy versus none. ††Severe atrophy versus moderate or none.
Table 3: Logistic linear regression analysis of associations between individual imaging signs and primary and secondary outcomes, adjusted for age, NIHSS score, and time to randomisation
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age, NIHSS score, and time to randomisation, to 
identify whether any combinations of imaging variables 
were associated with symptomatic intracranial 
haemorrhage or OHS score of 0–2. We then tested for 
interactions of imaging signs (presence, absence, or 
severity) and response to alteplase (adjusting for age, 
NIHSS score, and time to randomi sation) with 
symptomatic intracranial haemo r rhage, death within 
7 days, and OHS score of 0–2 at 6 months; as a 
secondary analysis, we assessed interactions of imaging 
signs and response to alteplase with an OHS score of 
0–1 and by ordinal OHS at 6 months (a more statistically 
sensitive ordinal model than analysis of dichotomous 
OHS categories). We tested whether associations 
between imaging signs and outcomes and imaging 
signs and alteplase diﬀ ered in patients randomised 
within 3 h, 3–4∙5 h, or 4∙5–6 h of stroke. We tested 
whether the response to alteplase diﬀ ered by the extent 
of early ischaemic signs (IST-3 score and ASPECTS 
score 0–7 vs 8–10), and we did a prespeciﬁ ed meta-
analysis of data from IST-3 with imaging data from 
other thrombolysis trials. We judged p values less than 
0·05 signiﬁ cant, except for analyses of interactions 
between imaging signs and response to alteplase, for 
which we used a signiﬁ cance level less than 0·01, to 
minimise false-positive results.
This trial is registered at ISRCTN.com, number 
ISRCTN25765518.
Role of the funding sources
The funding sources had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all data in the 
study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between May 1, 2000, and July 31, 2011, 3035 patients 
were recruited to IST-3 and underwent randomisation. 
Brain scans were available for 1507 patients assigned to 
alteplase and for 1510 controls; scans for 18 patients were 
not received at the central trials oﬃ  ce and, therefore, 
were excluded from analyses (ﬁ gure 1). Table 1 shows 
baseline clinical and imaging characteristics, which were 
well balanced between arms and no variables were 
missing.
Of 3017 prerandomisation brain scans, 2962 (98%) 
were obtained by CT and 55 (2%) by MRI. The expert 
panel judged 269 (9%) scans normal (ie, no early 
ischaemic or pre-existing signs); 1224 (41%) patients had 
early ischaemic signs (ie, visible infarct, whether or not 
pre-existing signs were also present) and 1524 (51%) had 
pre-existing signs (but no early ischaemic signs). The 
commonest early ischaemic sign was tissue hypo-
attenuation, seen in 1203 (40%) patients, and the least 
frequent sign was hyperattenuated artery, recorded in 
735 (24%) patients (table 1). Pre-existing signs were 
common: 1336 (44%) patients had signs of an old infarct, 
1547 (51%) had leukoaraiosis, and 2327 (77%) had 
evidence of atrophy.
Some strong associations were noted between 
individual imaging variables and age, NIHSS score, and 
time to randomisation (table 2; appendix pp 20–22). 
Every point increase in NIHSS score was associated with 
a roughly 10% increase in the odds of tissue 
hypoattenuation, swelling, hyper attenuated artery, or 
large lesion. Every delay of 1 h increased the odds of 
tissue hypoattenuation, but not other early or pre-existing 
structural signs. Every increase in age by 1 year decreased 
the odds of tissue hypo attenuation, large lesion, swelling, 
or hyper attenuated artery by about 2% (table 2), but the 
odds of old infarct, atrophy, and leukoaraiosis were 
increased.
Individually, all early ischaemic signs predicted worse 
outcomes (table 3) with the exception of severe hypo-
attenuation, although relatively few patients had this 
sign. Individually, of all pre-existing signs, only old 
infarct predicted symptomatic haemorrhage (table 2); 
no pre-existing signs predicted death within 7 days. 
Leukoaraiosis and severe atrophy predicted death by 
6 months, all pre-existing structural signs predicted 
reduced chance of being alive and independent (OHS 
score of 0–2) at 6 months, and leukoaraiosis and atrophy 
predicted diminished chance of a favourable outcome 
(OHS score of 0–1) at 6 months. Similar associations 
between imaging signs and outcomes were seen for 
OHS score 0–2 versus 
OHS score 3–6
Symptomatic intracranial 
haemorrhage
Odds ratio (95% CI) p Odds ratio (95% CI) p
Age (years) 0·96 (0·95–0·97) <0·0001 0·99 (0·98–1·01) 0·556
NIHSS score 0·83 (0·82–0·85) <0·0001 1·07 (1·04–1·10) 0·0001
Time to randomisation (h) 1·04 (0·96–1·13) 0·288 0·98 (0·83–1·15) 0·798
Alteplase versus control 1·12 (0·94–1·34) 0·196 6·71 (3·93–11·46) <0·0001
Antiplatelets at the time of stroke versus 
none
·· ·· 1·60 (1·07–2·38) 0·021
Small or medium lesion versus no lesion 0·85 (0·67–1·07) 0·173 ·· ··
Large or very large lesion versus no lesion 0·54 (0·39–0·74) 0·0001 ·· ··
Hyperattenuated artery versus none 0·71 (0·55–0·92) 0·009 1·61 (1·07–2·42) 0·023
Old infarct versus none ·· ·· 1·67 (1·13–2·46) 0·009
Mild leukoaraiosis versus none 0·76 (0·62–0·93) 0·009 ·· ··
Severe leukoaraiosis versus none 0·59 (0·45–0·79) 0·0003 ·· ··
Numbers of patients in each category are shown in table 1. Odds ratios indicate the increased or decreased odds of the 
clinical factor being present for a 1 year increase in age, a 1 point increase in NIHSS score, or a 1 h increase in time to 
randomisation. Models selected by stepwise logistic regression from full models shown in table 4. Additional time 
windows are shown in the appendix (pp 8–9). The ﬁ rst four variables were forced into all models. We used p≤0·05 as 
criteria for both forward and backward steps. Blank cells represent variables that were dropped as non-signiﬁ cant 
during stepwise selection. The ﬁ nal nominal p values take no account of model selection. Age, NIHSS score, and time 
to randomisation were entered into the model as continuous variables; thus the odds ratio for age represents the 
estimated change in odds of the outcome for a 1 year increase in age, with all other variables unchanged. The units for 
NIHSS score are points on a scale from 0 to 37 (maximum observed in this trial). Factors with three levels were either 
retained or excluded at each step; the method did not permit separate consideration of the individual 1 df contrasts 
comprising the three-level factors. NIHSS=National Institutes of Health Stroke Scale. OHS=Oxford Handicap Scale.
Table 5: Multivariate logistic regression models selected by stepwise logistic regression for symptomatic 
intracranial haemorrhage and functional outcome at 6 months
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patients randomised within 3 h, 3–4·5 h after stroke, and 
4·5–6 h after stroke (appendix pp 6–7).
The multivariate logistic regression model for 
symptomatic intracranial haemorrhage included age, 
NIHSS score, time to randomisation, individual imaging 
signs, alteplase, and use of antiplatelet drugs immediately 
before stroke.12 Increasing NIHSS score, alteplase, anti-
platelet treatment, and pre-existing old infarcts predicted a 
signiﬁ cantly higher risk of symptomatic intracranial 
haemorrhage (table 4). With standard stepwise model 
selection methods, retaining age, NIHSS score, time to 
randomisation, and treatment group, both old infarcts and 
hyper attenuated arteries were potentially signiﬁ cant 
predictors of symptomatic intracranial haemorrhage 
(table 5). The multivariate logistic regression model for 
good functional outcome (OHS score of 0–2) at 6 months 
showed that increasing age and NIHSS score were the 
strongest adverse predictors, but hyper attenuated arteries, 
large lesion, and leukoaraiosis each individually predicted 
less chance of a good outcome by about 25–30% (table 4). 
With standard stepwise regression methods, the selected 
model retained large lesion, hyperattenuated arteries, and 
0·25 1 2 5
Alteplase Control
Events/total Adjusted
odds ratio (99% CI)
Adjusted
p value
Acute ischaemic change on randomisation scan according to expert panel
No
Yes
Treatment with antiplatelet drugs in previous 48 h
No
Yes
Swelling
No
Yes
Tissue attenuation change
No 
Yes
Hyperattenuated arteries
No 
Yes
Lesion size
None visible
Small or medium
Large
Very large
Large lesion (none vs large or very large)
No
Yes
Old lesions
No 
Yes
Atrophy
No
Yes
Leukoaraiosis
No
Yes
Combination of large lesion, hyperattenuated arteries, and leukoaraiosis
None
One of three
Two of three
All three
0·567
0·394
0·357
0·560
0·517
0·897
0·849
0·529
0·960
0·237
0·668
 392/883 (44%)
 158/624 (25%)
 286/732 (39%)
 263/771 (34%)
 468/1152 (41%)
 82/355 (23%)
 395/892 (44%)
 155/615 (25%)
 475/1131 (42%)
 75/376 (20%)
 394/885 (45%)
 107/360 (30%)
 36/124 (29%)
 13/138 (9%)
 537/1369 (39%)
  13/138 (9%)
 326/822 (40%)
 224/685 (33%)
 176/346 (51%)
 374/1161 (32%)
 319/742 (43%)
 231/765 (30%)
 268/519 (52%)
 248/733 (34%)
 31/219 (14%)
  3/36  (8%)
1·17 (0·88–1·56)
1·06 (0·71–1·60)
1·03 (0·74–1·45)
1·20 (0·87–1·66)
1·09 (0·84–1·40)
1·37 (0·77–2·44)
1·17 (0·88–1·56)
1·06 (0·70–1·61)
1·16 (0·90–1·50)
1·01 (0·58–1·74)
1·18 (0·89–1·57)
0·93 (0·56–1·53)
1·52 (0·62–3·68)
1·41 (0·36–5·54)
1·13 (0·89–1·44)
1·41 (0·36–5·54)
1·18 (0·86–1·61)
1·05 (0·74–1·49)
1·07 (0·66–1·73)
1·12 (0·86–1·47)
0·99 (0·72–1·38)
1·24 (0·89–1·74)
1·08 (0·74–1·57)
1·14 (0·82–1·58)
1·18 (0·52–2·72)
5·77 (0·06–521·00)
 379/910 (42%)
 149/600 (25%)
 278/720 (39%)
 249/783 (32%)
 463/1171 (40%)
 65/339 (19%)
 383/922 (42%)
 145/588 (25%)
 452/1151 (39%)
 76/359 (21%)
 380/914 (42%)
 108/347 (31%)
 31/137 (23%)
 9/112 (8%)
 519/1398 (37%)
 9/112 (8%)
 311/859 (36%)
 217/651 (33%)
 172/344 (50%)
 356/1166 (31%)
 316/728 (43%)
 212/782 (27%)
 260/524 (50%)
 240/758 (32%)
  27/189 (14%)
  1/39  (3%)
Favours
control
Favours
alteplase
Figure 2: Forest plot showing the adjusted eﬀ ect of treatment and baseline imaging signs on Oxford Handicap Scale score 0–2 at 6 months
Data are adjusted for age, National Institutes of Health Stroke Scale score, and time to randomisation.
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leukoaraiosis, with coeﬃ  cients very similar to those in the 
full model (table 5). Similar eﬀ ects were seen in patients 
randomised 0–3 h, 3–4∙5 h, and 4∙5–6 h after stroke 
(appendix pp 8–9). However, potential diﬀ erences—eg, 
that tissue hypo attenuation (rather than old infarcts or 
hyper attenuated arteries) predicts symptomatic intra-
cranial haemor rhage in patients randomised 4∙5–6 h after 
stroke—should be interpreted with caution because of the 
weak signiﬁ cance level and smaller sample.
No interaction was recorded between any individual or 
combined imaging variable and alteplase, for either 
functional outcome (OHS score of 0–2, ﬁ gure 2) or 
symptomatic intracranial haemorrhage (ﬁ gure 3). 
Furthermore, no interaction was noted between any 
individual or combined image variable and alteplase in 
the ordinal shift analysis or in analyses restricted to 
patients randomised within 3 h of stroke or 3–4∙5 h or 
4∙5–6 h after stroke (appendix pp 10–17).
Despite the absence of deﬁ nite interactions between 
imaging signs and alteplase, the absolute increase in 
symptomatic intracranial haemorrhage after alteplase 
with combined imaging signs was substantial. The 
0·25 1 5 10 30
Alteplase Control
Events/total Adjusted
odds ratio (99% CI)
Adjusted
p value
Acute ischaemic change on randomisation scan according to expert panel 0·246
Treatment with antiplatelet drugs in previous 48 h 0·031
Swelling 0·318
Tissue attenuation change 0·244
Hyperattenuated arteries 0·568
Lesion size 0·221
Large lesion (none vs large or very large) 0·181
Old lesions 0·350
Atrophy 0·082
Leukoaraiosis 0·144
Combination of hyperattenuated arteries and old lesion 0·285
No 47/883 (5%)  5/910 (1%) 10·50 (3·09−35·60)
Yes 55/624 (9%) 11/600 (2%)  5·27 (2·21−12·60)
No 33/732 (5%)  9/720 (1%)  3·70 (1·39−9·89)
Yes 69/771 (9%)  6/783 (1%) 13·06 (4·31−39·60)
No 70/1152 (6%)  9/1171 (1%)  8·43 (3·35−21·20)
Yes 32/355 (9%)  7/339 (2%)  4·78 (1·59−14·30)
No 47/892 (5%)  5/922 (1%) 10·46 (3·08−35·50)
Yes 55/615 (9%) 11/588 (2%)  5·24 (2·20−12·50)
No 62/1131 (5%) 11/1151 (1%)  6·06 (2·58−14·20)
Yes 40/376 (11%)  5/359 (1%)  8·49 (2·45−29·40)
None visible 47/885 (5%)  5/914 (1%) 10·54 (3·11−35·80)
Small or medium 29/360 (8%)  6/347 (2%)  5·10 (1·57−16·60)
Large 11/124 (9%)  1/137 (1%) 12·96 (0·86−196·00)
Very large 15/138 (11%)  4/112 (4%)  3·24 (0·72−14·60)
No 87/1369 (6%) 12/1398 (1%)  7·94 (3·56−17·70)
Yes 15/138 (11%)  4/112 (4%)  3·24 (0·72−14·60)
No 42/822 (5%)  9/859 (1%)  5·17 (1·98−13·50)
Yes 60/685 (9%)  7/651 (1%)  8·76 (3·09−24·90)
No 19/346 (5%)  6/344 (2%)  3·11 (0·91−10·70)
Yes 83/1161 (7%) 10/1166 (1%)  9·02 (3·77−21·60)
No 45/742 (6%) 10/728 (1%)  4·67 (1·87−11·70)
Yes 57/765 (7%)  6/782 (1%) 10·48 (3·44−32·00)
None 26/590 (4%)  7/605 (1%)  4·00 (1·32−12·10)
One of two 52/773 (7%)  6/800 (1%)  9·70 (3·16−29·80)
Both 24/144 (17%)  3/105 (3%)  6·58 (1·30−33·30)
Favours
alteplase
Favours
control
Figure 3: Forest plot showing the adjusted eﬀ ect of treatment and baseline imaging signs on symptomatic intracranial haemorrhage within 7 days
Data are adjusted for age, National Institutes of Health Stroke Scale score, and time to randomisation.
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combination of old infarcts and hyperattenuated arteries 
(adjusting for age, NIHSS score, and time to 
randomisation) predicted nearly three-fold increased 
odds of symptomatic intracranial haemorrhage (odds 
ratio 2∙98, 95% CI 1∙71–5∙16) versus patients with 
neither sign (both signs present, absolute excess of 
events with alteplase 13∙8%, 95% CI 6∙9–20∙7; both 
signs absent, absolute excess with alteplase 3∙2%, 
1∙4–5∙1; appendix p 18). Similar absolute eﬀ ects on 
symptomatic intracranial haemorrhage were seen for 
patients randomised within 3 h of stroke (appendix 
pp 12–14). A diﬀ erence in absolute eﬀ ects was not seen 
for functional outcome at 6 months (OHS score of 
0–2) in the whole study group (appendix p 19) and by 
separate time windows (data not shown).
Discussion
To date, IST-3 is the largest randomised controlled trial of 
thrombolysis versus control after ischaemic stroke in 
patients for whom alteplase was judged promising but 
unproven. Although IST-3 was neutral on the primary 
endpoint (OHS score of 0–2),12 this ﬁ nding does not 
preclude the presence of clinically relevant interac-
tions with treatment. Therefore, we planned a priori 
a detailed secondary analysis of the association of 
imaging signs with thrombolysis eﬀ ects. Imaging signs 
are powerful prognostic markers; however, we recorded 
no unequivocal evidence that any individual imaging 
sign modiﬁ ed response to alteplase in patients presenting 
up to 6 h after ischaemic stroke. In this popula tion, 
no interaction was noted between extensive early 
ischaemia—commonly cited as an exclusion for throm-
bolysis treatment—and alteplase, which accords with 
previous ﬁ ndings (panel, ﬁ gure 4).6,8,12,22,31–38 Some 
combina tions of imaging features (eg, old infarct and 
hyperattenuated artery) were associated with an increased 
absolute excess of symptomatic intracranial haemorrhage 
after alteplase.
The plain CT scans obtained in IST-3 reﬂ ect imaging 
done in practice, with speed and accessibility being 
important factors in view of the steep time dependency 
of alteplase beneﬁ t.1,2,12,39 The scans reﬂ ected common 
problems, such as movement of the patient or oblique 
positioning. To date, the brain imaging dataset in IST-3 is 
the largest in an acute stroke trial (more than 7000 scans) 
to be read centrally. Scan reading was structured and 
masked, and follow-up was complete. We pretested the 
imaging rating system thoroughly17,18 and the assessors 
were skilled in acute stroke imaging. Although the expert 
panel might have detected subtle changes in tissue 
attenuation, we showed previously that those who were 
less experienced could still identify hyperattenuated 
arteries, established tissue ischaemia, and pre-existing 
structural changes with good reliability.17 These results 
should inform clinical practice. 
Although more patients were randomised within 3 h of 
stroke in IST-3 (n=846) than in any other previous trial,32 
we might have missed an interaction between an imaging 
sign and alteplase in the subgroup of patients treated 
within 3 h, because very few symptomatic intracranial 
haemorrhage events arose in controls, and the estimate 
of eﬀ ect on OHS score had wide CIs in each subgroup. 
Associations between clinical and imaging signs reﬂ ect 
the speciﬁ c IST-3 population; inference to the wider 
population with ischaemic stroke—including individuals 
not judged eligible for the trial—remains speculative. 
Few patients with obvious tissue hypoattenuation (ie, in 
whom the acute ischaemic tissue was of lower attenuation 
than normal grey and white matter) were included 
in the trial; severe tissue hypoattenuation, including 
Panel: Research in context
Systematic review
We searched the Cochrane Stroke Trials Registry, Medline, and Embase from 
January, 1990, to March, 2015, to identify all previous randomised controlled trials of 
thrombolysis versus control in acute ischaemic stroke with data for CT brain imaging and 
any interaction with thrombolysis.31 Three trials provided data for the extent of early 
ischaemic signs on CT brain imaging and functional outcome, in patients treated by 
thrombolysis and in controls, dichotomised on the Alberta Stroke Programme Early CT 
Signs (ASPECTS) score 0–7 and 8–10. Two trials tested intravenous alteplase 
(0·9 mg/kg)8,32 and one tested intra-arterial pro-urokinase.33 No other trials had data for 
imaging signs and outcome by treatment allocation for meta-analysis. In the three 
previous trials,8,32,33 patients with large early ischaemic lesions (ASPECTS score 0–7, n=521) 
had similar odds of good outcome (odds ratio 1·41, 95% CI 0·95–2·09) to those with small 
or no lesions (ASPECTS score 8–10, n=1029; odds ratio 1·59, 95% CI 1·24–2·04) after 
thrombolysis (test for subgroup diﬀ erences, p=0·61). In the third International Stroke 
Trial,12 patients with large lesions (ASPECTS score 0–7, n=729) had similar odds of good 
outcome (odds ratio 1·03, 95% CI 0·70–1·51) to those with small or no visible ischaemic 
lesions (ASPECTS score 8–10, n=2288; odds ratio 1·08, 95% CI 0·91–1·27). Combining all 
four trials (ﬁ gure 4) shows that patients with large infarcts (ASPECTS 0–7, n=1250) had 
similar odds of good outcome (odds ratio 1·20, 95% CI 0·91–1·58) to patients with small 
or no visible infarct (ASPECTS 8–10, n=3317; odds ratio 1·21, 95% CI 1·06–1·39) after 
thrombolysis (test for subgroup diﬀ erence, p=0·94). These ﬁ ndings accord with those of 
the Interventional Management of Stroke III trial (no interaction between ASPECTS score 
and thrombectomy)34 and trials in which the classiﬁ cation of early ischaemic signs on CT 
precluded meta-analysis with our data (no interaction between early ischaemic signs and 
streptokinase in 1292 patients within 6 h,35 or alteplase in 624 patients in the National 
Institute of Neurological Disorders and Stroke trial within 3 h of stroke)6 on functional 
outcome. No data were available in these trials for analysis of pre-existing CT signs and 
eﬀ ects of alteplase, nor to adjust for clinical prognostic variables.
Interpretation
Absence of an interaction between early ischaemic signs and thrombolysis has been 
disregarded by many up until now, perhaps because data came (in part) from trials that 
were neutral or that used a drug perceived to be harmful (eg, streptokinase). All data 
combined show that the extent of early ischaemic signs on CT per se should not deter 
treatment with alteplase. A meta-analysis of CT ﬁ ndings from individual patients in all 
trials of alteplase is planned as part of the Stroke Thrombolysis Trialists’ Collaboration, to 
test further the eﬀ ect of early ischaemic and pre-existing structural signs and 
combinations of imaging signs for interactions with alteplase, adjusted for baseline 
prognosis.2 Future trials should not only assess eﬀ ects of pre-existing and early ischaemic 
changes for interactions with acute stroke treatments but also consider use of imaging 
variables for minimisation in view of their strong independent prognostic value.
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appearances suggesting a lesion older than 6 h, was an 
exclusion criterion. Additionally, patients with extensive 
ischaemic lesions (ASPECTS 0–7) comprised only a 
quarter of the study population, although this proportion 
is higher than in any previous trial. Hence, although 
IST-3 was larger than previous trials, it might not have 
had enough statistical power to ascertain whether 
alteplase treatment in this subgroup of patients adds 
risk or beneﬁ t. We might have identiﬁ ed a spurious 
association, but we have been cautious in the 
interpretation, including 99% CIs for tests of interaction. 
The use of stepwise methods to identify parsimonious 
predictive models should not be interpreted as ruling out 
eﬀ ects of those imaging signs that were excluded from 
the models. Diﬀ erent subsets of the full set of predictors 
could produce almost equally good results in this dataset; 
therefore, further research to assess the contribution of 
diﬀ erent signs to the risk of adverse outcomes would be 
valuable.
Previous analyses of imaging predictors of the 
response to alteplase focused on individual acute 
ischaemic signs.20,40 Here, we have shown that pre-
existing signs are important. The association between 
symptomatic intra cranial haemorrhage and old infarcts 
could account for why the risk of symptomatic 
intracranial haemorrhage does not change with 
increasing time to alteplase up to 6 h;1,2 another factor 
present before the stroke, or that is independent of time 
after stroke, might increase risk. Worsening of 
functional outcome with old infarcts, atrophy, and 
leukoaraiosis might indicate increased susceptibility to 
acute ischaemia or alteplase hazards and could provide 
useful markers of so-called brain frailty.41 Further 
research is warranted to ascertain the strength of 
association between pre-existing signs on brain CT and 
clinical markers of brain frailty. Our ﬁ ndings also 
emphasise the value to future trials of minimising easy-
to-detect imaging prognostic signs to avoid baseline 
imbalances.
The presence of combinations of imaging signs in 
patients after stroke might provide additional infor-
mation to decision making when clinical uncertainty 
exists about the likely beneﬁ t of alteplase—eg, in a 
patient presenting close to the latest time window or for 
whom the likelihood of beneﬁ t was marginal.2 Additional 
factors aﬀ ecting risk of symptomatic intracranial 
haemorrhage (eg, taking antiplatelet drugs) might 
contribute to decision making in such patients. A hint, 
in stepwise modelling, that early ischaemic tissue 
hypoattenuation might be associated with increased risk 
Thrombolysis
Events Total
ASPECTS score 8–10
NINDS, 199532
ECASS II, 19988
PROACT 2, 199933
IST-3, 201212
Subtotal (95% CI)
Total events
Heterogeneity: p=0·002
Test for overall eﬀect: p=0·006
ASPECTS score 0–7
NINDS, 199532
ECASS II, 19988
PROACT 2, 199933
IST-3, 201212
Subtotal (95% CI)
Total events
Heterogeneity: p=0·39
Test for overall eﬀect: p=0·19
Total (95% CI)
Total events
Heterogeneity: p=0·01
Test for overall eﬀect: p=0·002
Test for subgroup diﬀerences: p=0·94
96
126
17
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Figure 4: Forest plot showing the interaction between response to alteplase and early infarct size in previous trials
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of symptomatic intracranial haemorrhage with alteplase 
4∙5–6 h after stroke (appendix pp 8–9) should be treated 
with caution, because this ﬁ nding was not conﬁ rmed in 
the formal test of interaction (appendix pp 12–17). 
Helpfully for routine practice, the key prognostic CT 
imaging variables identiﬁ ed here are easy to detect: 
hyperattenuated artery has the best observer reliability of 
all early ischaemic signs20 across a wide range of 
observers,17 and old infarcts, atrophy, and leukoaraiosis26,42 
are also easy to detect.17 Perceived diﬃ  culties in detecting 
early tissue hypoattenuation might have reduced 
conﬁ dence in use of CT scanning before 
alteplase.3 However, our ﬁ ndings conﬁ rm that neither 
early tissue hypoattenuation nor large infarct extent on 
ASPECTS score should exclude patients from alteplase, 
hopefully improving conﬁ dence in use of CT scanning 
in acute stroke.
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